FINWIRES · TerminalLIVE
FINWIRES

HF Sinclair's New $1.5 Billion Share Repurchase Program Seen as Positive, UBS Says

By

HF Sinclair's (DINO) new $1.5 billion stock repurchase program signals that management is committing to a more shareholder-driven capital allocation strategy rather than treating current refining profits as temporary, UBS Securities said Thursday in a report.

By returning surplus free cash flow and reaffirming its payout priorities, HF Sinclair is delivering on earlier promises and reinforcing confidence in how it deploys capital, the report said.

UBS maintained its buy rating on HF Sinclair stock with a $105 price target.

Price: $96.85, Change: $+0.33, Percent Change: +0.34%

Related Articles

Wire

Update: Magellan Financial Group Fiscal 2026 Operating Earnings, Revenue Down; Shares Fall 12%

(Updates to add stock movement in the headline and the last paragraph)Magellan Financial Group (ASX:MFG) logged AU$0.828 in operating earnings per share for fiscal 2026, compared with AU$0.898 a year ago, a Thursday filing showed.For the 12 months ended June 30, revenue and other income was AU$195.6 million versus AU$318.9 million previously, the Australia-listed financial services firm added.The board declared a final dividend of AU$0.255 per share, payable Sept. 16 to shareholders on record as of Sept. 2. A year ago, the company paid a final dividend AU$0.259 per share and special dividend of AU$0.21 per share.The board has revised the group's dividend policy from fiscal 2027, targeting a payout ratio of 60% to 90% of operating profit after tax.The company's shares fell 12% in recent Thursday trade.

ASX:MFG
Wire

Tenable to Join S&P SmallCap 600 Index

Tenable (TENB) will join the S&P SmallCap 600 index before market open on Aug. 31, the S&P Dow Jones Indices said in a late Wednesday statement.Tenable will replace Leggett & Platt (LEG), which is being acquired by Somnigroup International (SGI), according to the statement.

$LEG$SGI$TENB
Wire

NeoGenomics Wins Expanded Medicare Coverage for RaDaR ST Immunotherapy Monitoring

NeoGenomics (NEO) said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement.The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending.NeoGenomics shares rose 2.1% in after-hours trading.

$NEO